Loading…
Moderna, Inc. is projected to rise to $76.12 by 2027, a +12% move from its current price of $68.27. MRNA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $65.08 | $68.31 | $71.69 | +0.05% |
| Jul 15 | $63.82 | $68.34 | $73.18 | +0.11% |
| Jul 16 | $62.88 | $68.38 | $74.36 | +0.16% |
| Jul 17 | $62.11 | $68.42 | $75.37 | +0.22% |
| Jul 18 | $61.43 | $68.45 | $76.27 | +0.27% |
| Jul 19 | $60.84 | $68.49 | $77.11 | +0.32% |
| Jul 20 | $60.29 | $68.53 | $77.89 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $60.29 | $68.53 | $77.89 | +0.38% |
| Week 2 | $57.40 | $68.79 | $82.44 | +0.76% |
| Week 3 | $55.32 | $69.05 | $86.18 | +1.14% |
| Week 4 | $53.65 | $69.31 | $89.53 | +1.52% |
| Week 5 | $52.25 | $69.57 | $92.62 | +1.90% |
| Week 6 | $51.03 | $69.83 | $95.54 | +2.28% |
| Week 7 | $49.96 | $70.09 | $98.34 | +2.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Moderna, Inc. is a biotechnology company that provides messenger RNA medicines in the United States, Europe, and internationally. Its respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc.
and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna, Inc. (MRNA) is a biotechnology company. The stock is currently trading at $68.27 per share and has a market capitalization of $27.09B. In market rankings, Moderna is listed with a rank of 491.
The forecasted price path shows upside over time, with 2026’s average price at $68.27 and stronger gains projected for the long term, reaching an average of $105.45 by 2030, $254.56 by 2040, and $556.58 by 2050, accompanied by rising ROIs and bullish sentiment in the later years.
A major floor 57.4% below — a decisive break under it would weaken the trend.
The nearest floor, 33.1% below — buyers have tended to step in here.
The nearest ceiling, 19.8% above — a clean break opens room to run.
A major ceiling 48.5% above — clearing it would confirm fresh momentum.
Key MRNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MRNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $76.04 | Sell | $73.48 | Sell |
| MA 10 | $73.95 | Sell | $72.08 | Sell |
| MA 20 | $65.64 | Buy | $67.04 | Buy |
| MA 50 | $55.16 | Buy | $59.05 | Buy |
| MA 100 | $53.49 | Buy | $53.18 | Buy |
| MA 200 | $42.38 | Buy | $47.20 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.83 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 21.11 | Neutral |
| Williams %R (14) | -60.25 | Info |
| MACD (12,26,9) | 0.31 | Buy |
| ROC (12) | 11.92 | Buy |
| Bollinger %B (20,2) | 0.57 | Neutral |
| Stochastic %K (14) | 39.75 | Neutral |
| TRIX (15) | 1.61 | Buy |
| Awesome (5,34) | 17.88 | Buy |
| Ultimate (7,14,28) | 51.51 | Neutral |
| Momentum (10) | 8.52 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 74.65 | Sell |
| ADX (14) | 31.72 | Buy |
| ATR (14) | 3.14 | Info |
The 30-day technical picture is bullish. RSI14 is 50, suggesting neutral momentum near the midpoint, while the short-term trend shows constructive price action. The stock trades around the moving averages, with SMA50 at $55.16 and SMA200 at $42.38, indicating a recent upside bias.
Support is reported at $45.64 and resistance at $81.80, framing a defined near-term range. The 30-day range is $49.63 to $93.91, and annualized volatility stands at 90%, highlighting substantial movement potential in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $30.86 | $68.27 | $103.74 | 0% | Neutral | |
| $56.27 | $76.12 | $111.05 | +12% | Neutral | |
| $59.30 | $84.67 | $131.04 | +24% | Bullish | |
| $57.28 | $85.62 | $138.66 | +25% | Bullish | |
| $67.69 | $105.45 | $177.29 | +54% | Bullish | |
| $84.92 | $137.47 | $238.74 | +101% | Bullish | |
| $87.64 | $147.16 | $263.01 | +116% | Bullish | |
| $92.39 | $160.64 | $294.61 | +135% | Bullish | |
| $89.43 | $160.84 | $301.99 | +136% | Bullish | |
| $84.14 | $156.39 | $300.07 | +129% | Bullish | |
| $116.67 | $253.83 | $532.54 | +272% | Bullish | |
| $250.90 | $557.55 | $1,282.36 | +717% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $30.86 | $68.27 | $85.12 | +0.00% |
| August 2026 | $60.44 | $72.80 | $91.07 | +6.63% |
| September 2026 | $58.77 | $71.70 | $91.43 | -1.51% |
| October 2026 | $58.75 | $72.47 | $93.91 | +1.08% |
| November 2026 | $61.87 | $77.05 | $101.16 | +6.31% |
| December 2026 | $62.13 | $78.05 | $103.74 | +1.31% |
Click any year to see its month-by-month MRNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MRNA to range from $30.86 to $103.74 through 2026. The $68.27 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The MRNA price prediction for 2027 points to an average of $76.12 (low $56.27, high $111.05) — a potential gain of +12% on today's $68.27. Price action looks broadly range-bound.
In 2028, MRNA is projected to trade between $59.30 and $131.04, averaging $84.67 — a potential gain of +24% from today's $68.27. That is up +11% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Moderna, Inc.'s 2029 outlook centres on $85.62, within a $57.28 to $138.66 range. That is up +1% on the projected 2028 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2030, MRNA could reach as high as $177.29, with a base case around $105.45 and support toward $67.69 — roughly +54% from $68.27. Buyers look set to stay in control over this stretch.
Expect MRNA to range from $84.92 to $238.74 through 2031. The $137.47 average target implies a +101% move from current prices. That is up +30% on the projected 2030 average. Momentum favours further upside here.
The MRNA price prediction for 2032 points to an average of $147.16 (low $87.64, high $263.01) — a potential gain of +116% on today's $68.27. Buyers look set to stay in control over this stretch.
In 2033, MRNA is projected to trade between $92.39 and $294.61, averaging $160.64 — a potential gain of +135% from today's $68.27. That is up +9% on the projected 2032 average. Momentum favours further upside here.
Moderna, Inc.'s 2034 outlook centres on $160.84, within a $89.43 to $301.99 range. That is up 0% on the projected 2033 average. That marks a +136% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, MRNA could reach as high as $300.07, with a base case around $156.39 and support toward $84.14 — roughly +129% from $68.27. Momentum favours further upside here.
Expect MRNA to range from $116.67 to $532.54 through 2040. The $253.83 average target implies a +272% move from current prices. That is up +62% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The MRNA price prediction for 2050 points to an average of $557.55 (low $250.90, high $1,282.36) — a potential gain of +717% on today's $68.27. Momentum favours further upside here.
Investing $1,000 in MRNA today (≈ 14.647722 MRNA) could be worth
$8,166.78
+$7,166.78 (+717%) by 2050 · US Dollar
Based on the average projected MRNA price of $557.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MRNAwould be worth at today's price.
$1,000 invested in MRNA on Jul 10, 2025 (≈ 29.17153 MRNA) would be worth
$1,991.54
+$991.54 (+99.2%) today · 1.99× · US Dollar
Based on a MRNA entry price of $34.28 vs. today's $68.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $79.76 | $855.94 | -14.4% |
| 1 month ago | $45.99 | $1,484.45 | +48.4% |
| 3 months ago | $50.96 | $1,339.68 | +34.0% |
| 6 months ago | $33.84 | $2,017.43 | +101.7% |
| 1 year ago | $34.28 | $1,991.54 | +99.2% |
| All time (5.0y) ago | $246.66 | $276.78 | -72.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MRNA forecast.
Our base-case forecast reaches $140.00 around 2032.
Implied market cap at $140.00: $55.55B
The multi-year forecast envisions meaningful upside with a bullish trajectory through the late 2020s into the 2030s and beyond. The 2030 forecast shows an average price of $105.45 with a 54.5% ROI and bullish sentiment, signaling notable long-run appreciation. Looking further, 2040 projects an average price of $254.56 with a 272.9% ROI and bullish sentiment, underscoring strong longer-term upside.
By 2050, the average price is forecast at $556.58 with a 715.3% ROI and bullish sentiment, illustrating a substantial long-run growth pathway. Yearly snapshots also show continuing gains in the intermediate years, with 2027 at $75.96 (ROI 11.3%), 2028 at $85.03 (ROI 24.6%), and 2029 at $85.51 (ROI 25.3%), followed by higher averages and robust ROI into the 2030s and 2040s. These are estimates, not guarantees, and actual results depend on market conditions and other factors.
Tap a question to reveal the answer.
The forecast shows an average price of $105.45, with a min of $67.68 and a max of $177.34; the ROI is 54.5% and sentiment is BULLISH.
The long-run view shows rising averages and positive ROIs in the later years (e.g., 2030 ROI 54.5%, 2040 ROI 272.9%, 2050 ROI 715.3%), with bullish sentiment strengthening after 2026. However, near-term signals vary (2026 sentiment NEUTRAL; 2027 NEUTRAL), and these are estimates, not guarantees.
Yes. The 2040 forecast lists an average price of $254.56, with a max of $534.11 and a bullish sentiment.
The 30-day range is $49.63 to $93.91.
Current price is $68.27 and market cap is $27.09B; Moderna ranks 491.
Moderna, Inc. Community Discussion
0Share your Moderna, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.